Why the study?
Differentiating cardiac amyloidosis from hypertrophic cardiomyopathy remains clinically challenging, especially in patients with preserved LVEF and similar hypertrophy.
Does left ventricular global function index (LVGFI) by non-contrast CMR accurately differentiate cardiac amyloidosis from hypertrophic cardiomyopathy?
Does left ventricular global function index (LVGFI) by non-contrast CMR accurately differentiate cardiac amyloidosis from hypertrophic cardiomyopathy?
LVGFI derived from non-contrast CMR is a highly accurate novel marker for differentiating cardiac amyloidosis from hypertrophic cardiomyopathy, even in patients with preserved LVEF.
No takes yet. Share an insight, caveat, or question.
May support LVGFI for CA vs HCM differentiation on non-contrast CMR; leaves open prospective validation before clinical adoption.
Huang et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: